Typical and atypical carcinoid tumors belong to the neuroendocrine lung tumors. They have low recurrence and proliferation rate, lymph node, and distant metastases. Nevertheless, these tumors have shown a more aggressive behavior. In the last years, microRNAs were screened as new tumor markers for their potential diagnostic and therapeutic relevance. The expression of hsa-let-7b-5p, hsa-let-7f-5p, hsa-miR-222-3p, and their targets HMGA2 (highmobility group A2) and CDKN1B (cyclin-dependent kynase inhibitor 1B, p27 kip1 ) was evaluated in this rare small group of patients. We analyzed the clinical data of all typical and atypical carcinoid tumors of patients who underwent surgical operation at Marburg University Hospital (n = 18) from 2000. Quantitative reverse transcription polymerase chain reaction was performed in formalin-fixed paraffin-embedded tumor tissue versus four tumor-free lung tissue samples. HMGA2 was stable or downregulated; only one patient showed a significant overexpression. CDKN1B showed a significant overexpression or a stable level; it was downregulated in two samples only. Hsa-miR-222-3p resulted almost stable or overexpressed except for two samples (significantly downregulated). Hsa-let-7f-5p was stable or overexpressed in the majority of analyzed samples, whereas hsa-let-7b-5p was significantly downregulated. HMGA2 and CDKN1B are differently expressed between atypical and typical carcinoid tumors, thus representing valid biomarkers for the classification of the two tumor groups. Hsa-let-7f-5p and HMGA2 are inversely correlated. Hsa-miR-222-3p does not correlate with its predicted target CDKN1B.
Introduction
Neuroendocrine tumors of the lung represent 25% of all neuroendocrine cancer disease. Despite of their low percentage of all lung tumors (2%), its incidence is rising up to 6% each year. 1 The neuroendocrine lung tumors are divided into four groups: typical carcinoid (TC) tumor, atypical carcinoid (AC) tumor, large-cell neuroendocrine (LCNEC) tumors, and small-cell lung cancer (SCLC). In large surgical series, TC (80%) and AC (8%-13%) represent the most common neuroendocrine lung tumors. 2 TC tumors are characterized by low proliferation rate and small mitosis rate (<2 per 2 mm 2 ) without necrotic areas. The proliferation index Ki-67 is lower than 5%. 3 AC tumors show a high proliferation rate, a high mitosis rate (>2 per 2 mm 2 ), and a focal cell necrosis. The proliferation marker Ki-67 is usually lower than 20%. 3 The prognosis of patients affected by carcinoid tumors is better if compared with the commonly bad prognosis of LCNEC tumors and SCLC. However, lymph node metastases can occur within the TC tumors. 4 Unfortunately, despite histological and immune-histological diagnosis, the aggressiveness of the carcinoid tumors can be hardly foreseen.
In recent years, the role of microRNAs (miRNAs) in various malignant tumors has been intensively studied. 5 Several observations suggest for miRNAs a diagnostic, prognostic, and therapeutic potential. 6 Further studies highlighted the occurrence of miRNAs' cluster mutations as a main cause of cancer development. 7 Up to now, few studies about miRNAs focus on neuroendocrine lung tumors. Dossing et al. 8 described the downregulation of the miR-129-5p and the let-7 family miRNAs in neuroendocrine lung tumors that leads to an upregulation of their targets Egr1, G3bp1, HMGA2, and BACH1. Altered expression of miR-21, miR-155, and hsa-let-7a was observed in neuroendocrine tumors of the lung. In this study, there were no differences in the expression profile between typical and AC tumors. MiR-21 and miR-155 were differentially expressed according to the histological subtypes of pulmonary neuroendocrine tumors. 9,10 Mairinger et al. screened 763 miR-NAs in 12 different neuroendocrine lung tumors (TC, AC, LCNEC, and SCLC). Four showed a positive correlation with the histological types of neuroendocrine tumors: miR-18, miR-15b, miR-335, and miR-1201. 11 HMGA2 belongs to a family of small chromatin-associated non-histone proteins and acts as architectural transcription factor. 12, 13 HMGA2 is normally expressed during embryogenesis and tissue development and suppressed in normal differentiated tissue. Its overexpression has been shown in several benign and malignant tumors and it is inversely correlated with the expression of Let-7 family miRNAs. 14, 15 Let-7 family miRNAs have been shown to be highly expressed in normal thyroid tissue. 16 Up to now, the correlation between HMGA2 and let-7 miRNAs in carcinoid tumors has not been described yet.
CDKN1B (p27 kip1 ) is responsible for inhibiting the cyclin-dependent kinases and arrest the cell cycle in adverse event of genotoxic stress. Its aberrant expression could exert a pro-oncogenic role. 17 Its mutation is linked with multiple endocrine neoplasia (MEN) syndromes. 18 CDKN1B has been recently identified as reference gene in neuroendocrine lung cancer. 19 It is a target of hsa-miR-222-3p as it has been observed in several tumors. [20] [21] [22] We aimed to analyze the expression of hsa-let-7b-5p, hsa-let-7f-5p, and their related target HMGA2 in a panel of typical and AC tumor samples. Furthermore, we wanted to investigate the expression of hsa-miR-222-3p and its target CDKN1B (p27 kip1 ) in the same group of samples.
Subjects and methods

Basic clinical data collection
In all, 18 patients with typical and AC tumors in a time interval between 2000 and 2014 underwent surgical operation at Marburg University Hospital. On the basis of a complete prospective documentation, we gathered the following data for each patient: sex, age at operation time (years), smoker status at operation time (yes/no), tumor side and localization, pre-operative findings of the positron emission tomography-computed tomography (PET-CT) and the DOTATOC PET-CT (positive/negative), Ki-67 index (%), number of lymph nodes tumor-stricken taken during the operation, as well as the follow-up (between 3 and 15 years). For the parameters, the median and range were determined in each case. Statistical analysis was performed with GraphPad Prism 6.0 (GraphPad Prism, La Jolla, CA, USA).
Sample collection
Tumor tissue was collected when patients, diagnosed for typical and AC tumors, underwent surgical resection of a lung tumor at the University Hospital of Marburg. A total of 8 typical and 10 AC tissue samples were collected between 2000 and 2014 and were all included in the study. The study was conducted under the approval of the Ethics Committee of Marburg University Hospital (No. 68/14), and all patients signed out the inform consent. Four samples of tumor-free lung tissues were collected from formalin-fixed paraffin-embedded blocks obtained from patients who underwent surgical resection of lung adenocarcinoma and metastasis of colon carcinoma. The tissue was found tumor free after pathological examination and was used as control for the following experiments.
RNA isolation
Total RNA, including short RNA, was isolated from typical and atypical pulmonary neuroendocrine tumors; 10 µm slices were cut from formalin-fixed paraffin-embedded blocks and processed by FFPE XS Kit (MACHEREY-NAGEL GmbH & Co. KG, Dueren, Germany) following the manufacturer instructions. Total miRNAs-enriched RNA amount was measured with NanoDrop Lite (Thermo Fisher Scientific, Darmstadt, Germany) and its quality was assessed by the 260/280 absorbance ratio.
In silico analysis
In order to reveal potential targets of these miRNAs, we performed in silico analysis in four independent databases: miRanda (http://www.microrna.org), miRDB (http:// mirdb.org/miRDB/), RNA22-HSA (https://cm.jefferson. edu/rna22/), and TargetScanHuman (http://www.targetscan.org).
Quantitative reverse transcription polymerase chain reaction
MiRNA-enriched RNA lysates were reverse transcribed with miScript II RT Kit (Qiagen, Hilden, Germany). Complementary DNA (cDNA) was amplified with miScript SYBR Green PCR Kit using commercially available hsa-let-7b-5p (MS00003122), hsa-let-7f-5p (MS00006489), and miR-222-3p (MS00007609) miScript Primer Assays (Qiagen). RNU6B (MS00029204) was amplified as reference miRNA. For the amplification of HMGA2 and CDKN1B, Sso Fast Eva Green from BioRad (Munich, Germany) was used. HMGA2 (QT01157674), CDKN1B (QT00998445), and glyceraldehyde 3-phosphate dehydrogenase (GAPDH; QT01192646) were purchased from Qiagen; quantitative polymerase chain reaction (qPCR) was run on CFX96 (BioRad). GAPDH was amplified as reference gene transcript and used for normalization of target gene quantification cycles. Tumorfree lung tissue was also processed for miRNAs and target expression.
For final representation, PCR data (fold change compared to tumor-free lung tissue) were classified as follows:
↑ >10, ↑↑ >100, ↑↑↑ >1000, ↑↑↑↑ > 10,000 fold and ↓ <0.5, ↓↓ <0.1, and ↓↓↓ <0.01 fold
Statistical analysis
Statistical analysis of PCR results was performed using CFX Manager (BioRad) and Rest 2008. Significance was calculated using the t-test for paired samples; p < 0.05 was regarded as significant. Each tumor probe was normalized against the mean result of four tumor-free lung tissue samples.
Results
Demographic patient data collection and tumor stage
Median age was 60.5 years (range: 39-71 years) for the TC tumors and about 59 years (range: 31-72 years) for the atypical ones. The gender distribution for TC was 3 men versus 5 women and for AC 5 men versus 5 women. The ratio between the smoker and the non-smokers in both groups was equal: 62.5% of the patients were non-smokers. In the group of the TC tumors, six tumors were detected in the right lobe and two in the left lobe of the lung. Nine of the AC tumors were localized in the right side and only one in the left side. DOTATOC-PET-CT scan was positive in 7 of the TC tumors, whereas 6 of the AC tumors were positive. The fludeoxyglucose (FDG)-PET-CT scan showed a low sensitivity in both kinds of tumors-TC: 7 negative; AC: 5 negative. All patients received a complete resection of the tumors including a radical lymphadenectomy. The TC tumors were classified as G1 tumors. Seven AC tumors were classified as G1, two G2, and one G3. All resected tumors were classified as T1 with a size smaller than 2 cm. The median of resected lymph nodes in TC tumors was 18.5 (range: 4-34) and in AC tumors was 19 (range: 10-39). The lymph nodes were tumor free in 7 of the TC tumors after histological examination. Only in one case, a N1 lymph node was estimated histologically as tumor-stricken. The AC tumors showed one N2 and one N3 tumor infiltrating nodules (for details, see Table 1 ). After 3 years, all patients were alive without any local recurrence or new distant Table 1 . Clinical basic demographic data of the patients (n = 18; comparison between the typical carcinoid (TC; n = 8) and atypical carcinoid (AC; n = 10) groups). 
metastases of the tumor. One patient was disease free after 15 years.
HMGA2 and CDKN1B expression in typical and AC tumors
HMGA2 is a non-transcription factor involved in mediating the transcriptional activity of E2F, thus promoting the proliferation and tumor invasiveness. 23 For this reason, it was found useful to evaluate its expression in neuroendocrine tumors of the lung. As shown in Figure 1 (lower panel), HMGA2 was detectable in 16 out of 18 samples collected from patients.
The majority of samples (n = 10) showed a significant downregulation (<0.01-fold) of HMGA2 transcript in comparison to tumor-free lung tissue. Five samples showed an unvaried expression and one sample only showed a significant upregulation (>10-fold; Table 2 ).
CDKN1B is responsible, together with CDKN1A (p21 Cip1 ), for cell-cycle block by inhibiting the cyclindependent kinases. 24 Its expression could represent a valid biomarker for the slow proliferating carcinoid tumors. Analysis of expression confirmed that CDKN1B was detectable in 16 out of 18 collected samples. Its expression (Figure 2 (lower panel) ) was generally stable in six samples. Eight samples showed a significant overexpression (>100-fold) of CDKN1B. Two samples only showed a significant downregulation (<0.1 <0.01-fold) of CDKN1B transcript in comparison to tumor-free lung tissue ( Table 2 ). HMGA2 is generally downregulated in neuroendocrine tumors and support their low proliferation rate. Furthermore, the stable/upregulated expression of CDKN1B could strongly confirm the apparent steady state of carcinoid tumor and it could be used as valid biomarker for this malignant disease.
Expression of hsa-let-7f-5p and hsa-let-7b-5p in typical and AC tumors
Let-7 miRNAs exert a tumor-suppressor role 7, 14 and their detection could represent a valuable diagnostic marker. Let-7 miRNAs were detectable in all samples of patients affected by carcinoid tumors (n = 18) included in the study. Hsa-let-7f-5p was almost stable (n = 7) or overexpressed (n = 6) in carcinoid tumor samples (>100-fold). Its expression was downregulated in five samples only (<0.01-fold; Figure 1 (upper left panel) ).
As shown in Figure 1 (upper right panel) , hsa-let-7b-5p, another member of Let-7 family, resulted downregulated in the majority of samples (n = 13; <0.01-fold). Only three samples showed a significant upregulation of it (>100fold). Two samples showed a stable expression in comparison to tumor-free lung tissue used as control. Figure 2 (upper panel) shows the expression of hsa-miR-222-3p, a miRNA with oncogenic property. The level of hsa-miR-222-3p was detectable in all patient samples (n = 18). Its expression was found stable or upregulated in the majority of samples (n = 14; >100-fold). Four samples showed a downregulation of the above-mentioned miRNA (<0.1-fold; Table 2 ).
The general stable/overexpression of hsa-let-7f-5p could represent a valid biomarker for carcinoid tumor and could aim to become a positive prognostic factor. Moreover, its significant upregulation could be inversely correlated with the significant low expression of its validated target HMGA2 (Figure 1 (lower panel) ).
Hsa-miR-222-3p overexpression could characterize carcinoid tumor profile and represent a future marker for the diagnosis of this aggressive malignancy. No correlation was found with its putative target CDKN1B.
Distribution of miRNAs and predicted targets by atypical and typical subgroups
The expression of HMGA2, CDKN1B, hsa-miR-222-3p, hsa-let-7f-5p, and hsa-let-7b-5p was analyzed independently in the two subgroups of AC and TC tumors. The median of quantified expression was calculated after excluding oversized values. As shown in Table 3 , the AC tumors showed a significant downregulation (0.285) of HMGA2, whereas the typical showed a stable expression (0.775). Additionally, CDKN1B overexpression was observed in TC tumors (2.43) . The atypical tumors were characterized by a stable expression of CDKN1B (1.33) .
Concerning the analyzed miRNAs, hsa-miR-222-3p was stably expressed in both tumor subgroups. Interestingly, hsa-let-7f-5p was slightly downregulated (0.655) in typical tumors and stably expressed in atypical (1.53) . No differences were observed for hsa-let-7b-5p that was significantly suppressed in both tumor subgroups.
To summarize, it could be observed that AC tumors could be classified for their low expression rate of HMGA2 and stable rate of CDKN1B. TC tumors could be grouped for their stable expression of HMGA2 and high rate of CDKN1B.
Discussion
Our study examined the expression of two miRNAs belonging to Let-7 family and hsa-miR-222-3p in typical and AC tumors. It has been previously shown that Let-7 family miRNAs are normally expressed in normal adult tissue and they exert a tumor-suppressor role. Their suppression is correlated with tumor progression and invasiveness. The re-expression of let-7 miRNAs lead to cell death and loss of tumor aggressiveness. 14, 25 Moreover, Let-7 miRNAs are able to target not only oncogenes but also transcripts of gene expressing membrane transporters like SLC5A5. In silico analysis has shown that SLC5A5 is a target of Let-7 family miRNAs. Interestingly, it was found that SLC5A5 is inversely correlated with miRNAs belonging to Let-7 family in thyroid cancer. 26 Here, it was shown a stable or upregulated expression of hsa-let-7f-5p, whereas hsa-let-7b-5p resulted strongly suppressed in human carcinoid tumors. Interestingly, it was observed that HMGA2, a predicted target of hsa-let-7 miRNAs, is strongly suppressed in all analyzed samples of AC tumor included in this study. This study furthermore confirmed the inverse correlation existing between hsalet-7f-5p and HMGA2, while no correlation was found with hsa-let-7b-5p. This finding is supported by previously published studies showing that suppression of Let-7 miR-NAs restores HMGA2 and promotes tumor metastasis in neuroendocrine tumors. 8, 27 Interestingly, the expression of HMGA2 could represent a marker to characterize the TC tumors because of its stable expression, whereas its level is significantly low in AC tumors. Additionally, the expression of hsa-miR-222-3p was analyzed. The majority of patient samples showed a significant overexpression of this miRNA. Furthermore, in silico analysis showed that CDKN1B represents one of the putative targets of hsa-miR-222-3p.
Analysis of CDKN1B showed a stable and/or strong significant overexpression of its transcript. Interestingly, the expression of cyclin-dependent kinase (CDK) inhibitor p27 could block the cell cycle and keep the cells in a steady state or at low proliferation rate as previously shown. 28 Additionally, the high expression rate of CDKN1B could exert a CDK-independent role with oncogenic properties as previously shown 17 that could also clarify its overexpression in pulmonary neuroendocrine tumors. The results showed that no correlation was found between hsa-miR-222-3p and CDKN1B, which could not be clarified in this study. It could be possible that CDKN1B is under the control of other miRNAs expressed in neuroendocrine tumors of the lung as shown in prostate cancer for miR-24. 29 Furthermore, CDKN1B was differently expressed in the two subgroups of carcinoid tumors; in particular, its level was significantly high in TC tumors, whereas it was found stable in atypical tumors.
Despite the small group of study sample, we could clarify the expression status of two of the miRNAs belonging to Let-7 family and hsa-miR-222-3p in carcinoid tumors. First, the general expression of hsa-let-7f-5p could be considered as valid biomarker in patient samples showing a correlated suppression of its predicted target HMGA2, as shown here for AC tumors.
Furthermore, the overexpression of hsa-miR-222-3p could be a valid diagnostic marker as shown for other disorders and tumors. [30] [31] [32] Finally, the expression of CDKN1B would represent a double-edged diagnostic factor and/or predictor of therapy response, as shown for osteosarcoma, breast cancer, and ovarian cancer, [33] [34] [35] especially for the identification of TC tumors showing higher CDKN1B expression than the atypical tumors. This issue needs to be confirmed in further studies on lung carcinoid tumors.
